Supplementary File 1: Inonotus Hispidus Mechanisms in Renal Cell Carcinoma

49 bioactive compounds from Inonotus hispidus were identified via UHPLC-Q-Exactive HRMS and literature mining. The research by Yujie Wei, last updated in May 2026, used network pharmacology, molecular docking, and in vitro/vivo experiments to investigate the fungus's antitumor mechanisms in clear cell renal carcinoma. The study identified 169 overlapping targets and core pathways like PI3K/Akt/mTOR signaling.

Use Cases

• Validate network pharmacology predictions based on the 49 identified bioactive compounds.
• Study PI3K/Akt/mTOR pathway regulation in cancer based on the described in vitro and in vivo experimental results.
• Benchmark molecular docking simulations based on the binding affinities reported for key compounds like cerevisterol and withanolide.
• Design follow-up biological experiments based on the core targets AKT1, EGFR, CTNNB1, STAT3, and BCL2 identified in the analysis.

Strengths

• Identifies 49 specific bioactive compounds and 169 overlapping molecular targets.
• Integrates multiple methodologies: network pharmacology, molecular docking, and in vitro/vivo validation using 769-P and ACHN cell lines.
• Results are supported by specific experimental assays including CCK-8, colony formation, apoptosis, wound-healing, and Western blot.

Limitations

• The dataset is a single 12.9 KB DOCX file, suggesting limited raw data scope.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

Yujie Wei via figshare.

Collection Method

Bioactive compound identification via UHPLC-Q-Exactive HRMS and literature mining; target prediction via SwissTargetPrediction and public databases; experimental validation.

Freshness

Last updated 2026-05-12 05:42:18; freshness should be verified.